Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.73 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734003 | 1.00 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DNFE2L2 | |
| SCHEMBL4733999 | 1.00 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DNFE2L2 | |
| SCHEMBL4619766 | 0.91 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL4927520 | 0.86 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4821336 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27684141 | 0.85 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL4821329 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8561565 | 0.82 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL4816601 | 0.81 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8500731 | 0.81 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885697-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20060276515-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
| WO-2006121719-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276515-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | PDE4A 1392/4885PDE4B 1612/4885PDE4C 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.